Recombinant factor VIIa: a review on its clinical use.
Recombinant activated factor VII (rFVIIa) (NovoSeven) is a novel hemostatic agent originally developed to treat bleeding episodes in hemophilic patients with inhibitors against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. Based on a literature search including PubMed, references from reviews, and abstracts from the most important meetings on this topic, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterized clinical applications.
Franchini
Massimo
M
Servizio di Immunoematologia e Trasfusione - Centro Emofilia, Azienda Ospedaliera di Verona, Italy. massimo.franchini@mail.azosp.vr.it
D005167:Factor VII / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000188:drug therapy; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa